Redeye has grown more confident in the outlook for BioInvent following i) recent progress for the most important projects as well as ii) the transforming (>SEK 600m) capital raise. Going forward, BioInvent’s transition into a clinical stage immune-oncology player with a broad pipeline should gather momentum, which we argue should drive valuation higher. We raise the base case to SEK 2.8 (2.5).
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/